Cannara Biotech Inc.

LOVE

CA13765U2002

Healthcare Facilities & Services

Market Closed - Toronto S.E. Other stock markets 03:17:35 2024-05-17 pm EDT			5-day change	1st Jan Change
0.81 ^CAD	+1.25%		0.00%	-2.41%

Apr. 29	Cannara Biotech Turns Negative As Reports Wider Q2 Net Loss Vs a Year Ago, Despite Revenue up 51%	MT
Apr. 29	Cannara Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	CI

Cannara Biotech Inc. Appoints Mary Durocher as New Board Director

May 15, 2020 at 05:00 pm EDT

Cannara Biotech Inc. announced the appointment of Mary Durocher as a Director on Cannara's Board, effective immediately. Ms. Durocher is President and Chief Consultant of Fox D Consulting.

Latest news about Cannara Biotech Inc.

Cannara Biotech Turns Negative As Reports Wider Q2 Net Loss Vs a Year Ago, Despite Revenue up 51%	Apr. 29	MT
Cannara Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	Apr. 29	CI
Cannara Biotech Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023	Jan. 29	CI
Cannara Biotech Inc. Reports Earnings Results for the Full Year Ended August 31, 2023	Dec. 07	CI
Cannara Biotech's Fiscal Q4 Profit, Revenue Grows; Up 9.4%	Dec. 07	MT
Cannara Biotech Inc. Reports Earnings Results for the Fourth Quarter Ended August 31, 2023	Dec. 07	CI
Tranche Update on Cannara Biotech Inc.'s Equity Buyback Plan announced on November 30, 2022.	23-07-27	CI
Cannara Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	23-07-27	CI
Tranche Update on Cannara Biotech Inc.'s Equity Buyback Plan announced on November 30, 2022.	23-04-24	CI
Cannara Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	23-04-24	CI
Cannara Biotech Down Near 8% As Enters into an Automatic Share Purchase Plan	23-02-28	MT
Cannara Biotech Converts CA$5 Million Debenture, Plus Interest, into Nearly 30 Million Shares for Olymbec Investments	23-02-10	MT
Tranche Update on Cannara Biotech Inc.'s Equity Buyback Plan announced on November 30, 2022.	23-01-23	CI
Cannara Biotech Inc. Reports Earnings Results for the First Quarter Ended November 30, 2022	23-01-23	CI
Cannara Biotech Reports Normal Course Issuer Bid for Common Shares	22-11-30	MT
Cannara Biotech Inc. announces an Equity Buyback for 15,000,000 shares, representing 1.71% of its issued share capital.	22-11-30	CI
Toronto Stocks Rise, Cannara Biotech Shares Climb on 4Q Results	22-11-25	DJ
Cannara Biotech Gains 5% as Q4 EPS Unchanged at $0.01 Vs Year Ago; Revenue $11.9 Million Vs $6.5 Million	22-11-25	MT
Cannara Biotech Q4 EPS Unchanged at $0.01 Vs Year Ago; Revenue $11.9 Million Vs $6.5 Million	22-11-25	MT
Cannara Biotech Inc. Reports Earnings Results for the Full Year Ended August 31, 2022	22-11-25	CI
Cannara Biotech Inc. authorizes a Buyback Plan.	22-11-10	CI
Cannara Releasing 14 SKUs Across Ontario, Quebec Under Tribal, Nugz, and Orchid CBD Brands	22-09-30	MT
Cannara Biotech Inc. Announces Entry into the British Columbia Market and the Launch of Its First Vape Cartridge and Vape Accessory, Tribal G Mint and Uni Pro Ark	22-09-20	CI
Cannara Signs an Exclusive Brand Partnership with Exotic Genetix in Canada	22-08-03	CI
Cannara Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2022	22-07-27	CI

Cannara Biotech Inc. is a Canada-based vertically integrated producer of premium-grade cannabis and cannabis-derivative products for the Quebec and Canadian markets. It operates through its wholly owned subsidiaries, Cannara Biotech (Quebec) Inc. and Cannara Biotech (Valleyfield) Inc. The Company owns two mega facilities based in Quebec spanning over 1,650,000 square feet, providing the Company with 100,000 kilograms of annualized cultivation output. It operates in two segments: Cannabis operations and Real estate operations. The Cannabis operations, which encompasses the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and other cannabis services (Cannabis operations). The Real estate operations, related to the Farnham and Valleyfield building (Real estate operations). The Companyâs brand portfolio includes Tribal, Nugz, and Orchid CBD. Orchid CBD is a wellness brand that provides premium CBD-dominant cannabis.

Sector

Healthcare Facilities & Services

Calendar

2024-07-24 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Medical Farming

	1st Jan change	Capi.
CANNARA BIOTECH INC.	-2.41%	53.59M
CRUCIAL INNOVATIONS CORP.	-.--%	339M
AYR WELLNESS INC.	+52.26%	299M
ASCEND WELLNESS HOLDINGS, INC.	+35.05%	279M
INTERCURE LTD.	+168.19%	152M
JUSHI HOLDINGS INC.	+45.65%	138M
THE CANNABIST COMPANY HOLDINGS INC.	-41.95%	128M
IANTHUS CAPITAL HOLDINGS, INC.	-28.57%	122M
4FRONT VENTURES CORP.	+34.62%	118M
BAKHU HOLDINGS, CORP.	+100.00%	60.26M

Medical Farming